Gentamicin (GM) is an aminoglycoside antibiotic used in Gram-negative infections. It has shown 15-30% nephrotoxicity as a common side effect that manifests as nonoliguric renal failure with a slow rise in serum creatinine and hypoosmolar urinary output after several days of treatment. [1] In Ayurveda, such side effects are considered as the poisonous effects of low potent poisons known as gara viṣa. Gara viṣa is the term used for any artificial poison, which may kill the person or if retained in the body for prolonged period may produce symptoms like generalized edema, anemia, enlargement of abdomen, etc., by virtue of its potency. [2] Bilvādi agada [3] (BA) is an antivenom formulation indicated in the context of snake venom management. It is also indicated in low potent poisons. It [4] Therefore, the present experimental study was conducted to evaluate the nephroprotective activity of BA in GM induced nephrotoxicity animal model.
MATERIALS AND METHODS

Materials
• The material used for the present work BA was procured from Good Manufacturing Practices certified standard pharmacy • GM and normal saline were purchased from the local market, manufactured by a standard company • Eighteen healthy male Wistar rats were procured from licensed breeders (Venkateswara Pvt. Ltd., Bangalore) weighing 200 g (±20 g) and were 8-12 weeks of age.
Experimental study design
The animal experiment was approved by the Animal Ethics Committee of the institute. Animals were housed in stainless steel cages under standard laboratory conditions at ambient temperature 22 ± 3°C and 45-55% relative humidity with 12 h natural light/dark cycle. Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines were followed throughout the study. The animals were provided ad libitum with tap water and fed with standard diet (Amruta feeds, VRK's Scientist's Choice Laboratory Animal Feed, Baramati).
Eighteen rats were randomly assigned to three groups equally.
• Normal control, injected intraperitoneal (i.p.) normal saline for 8 days; • GM treated group, injected i.p. GM (80 mg/kg) for 8 days; • GM + BA treated group, injected i.p. GM (80 mg/kg) along with oral administration of BA 216 mg/each rat weighing ~200 g for 8 days.
Dose calculation of BA
Rat dose = Human dose in grams × surface area of Wistar strain rats in square meter. [5] Assessment parameters -Biochemical tests -Animals were anaesthetized by light ether anesthesia and blood was drawn through cardiac puncture and collected in labeled plain vials. Animals were put in metabolic cages on 8 th day and urine was collected on 9 th day. Blood urea nitrogen (BUN), serum creatinine, serum electrolytes -Potassium, sodium, chlorine, phosphorus, calcium, urine creatinine, urine electrolytes -Potassium, sodium, chlorine were assessed as markers of toxicity.
Histopathological assessment
Kidneys were collected immediately after sacrificing and transferred to 10% formalin solution in separate labeled containers.
Blood, urine, and kidney samples were sent to Jeevan Diagnostic Center, Belgaum for biochemical investigations and histopathological study.
Statistical analysis
All the values were expressed as mean ± standard error and data were analyzed by applying one-way analysis of variance followed by the Dunnett's test for multiple comparisons using SPSS software version 21.0 (IBM corporation). P < 0.05 was considered as statistically significant.
RESULTS
Gentamicin produced significant changes in the levels of serum creatinine, urine creatinine, urine potassium, urine chloride, urine sodium, and BUN when compared to control group indicating GM induced toxicity. Whereas BA treated group produced significant changes only in the levels of serum creatinine, urine creatinine, and urine potassium showing protective effect of the drug on these parameters.
There were no significant changes in the levels of serum potassium, sodium, chloride, calcium, and phosphorus in all the three groups [ Tables 1 and 2 ].
All parts of kidney showed normal appearance in control group except for mild congestion. Treatment with GM caused acute renal damages which were evident by marked glomerular congestion, interstitial edema, tubular necrosis, and interstitial hemorrhage [ Figure 1 ]. These changes were again reduced in BA treated group which were evident by mild congestion and prevention of tubular degeneration, interstitial edema showing protective effect of drug [ Table 3 ].
DISCUSSION
Renal failure denotes failure of the excretory function of kidney, leading to the retention of nitrogenous waste products of metabolism in blood, failure of regulation of fluid, and electrolyte balance along with endocrine dysfunction. This happens only when the damage exceeds 25% of normally functioning nephrons. It occurs due to exogenous agents and endogenous agents like radiocontrast agents, cyclosporins, antibiotics like aminoglycosides, chemotherapeutic agents, organic solvents, acetaminophen, and illegal abortifacients.
Kidneys becomes one of the important targets for toxicity more than any other organ of the body due to high levels of toxins being delivered to the kidney due to the higher blood supply. [6] GM, an aminoglycoside antibiotic has nephrotoxicity as a common side effect.
Gentamicin induced nephrotoxicity is the 2 nd category of acute renal failure (ARF). It is an intra-renal/intrinsic ARF and accounts for 69% of all cases of ARF. It occurs due to damage to the parenchyma of kidney. Acute tubular necrosis is more common form of intrinsic ARF. [6] Gentamicin binds to the receptors located on the apical membrane of proximal tubular cells. It is postulated that GM being a cationic drug binds to the anionic phosphoinositides located on the apical membrane. The binding of drug receptor is followed by pinocytosis of the drug-receptor complex to a secondary lysosome. Within the lysosome, GM might interfere with the catabolism of receptor by directly inhibiting phospholipase C, by modifying substrate-enzyme affinity or by raising the intralysosomal pH above the effective range of enzyme. Inhibition of the activity of lysosomal phospholipase C leads to the accumulation of phosphatidylinositol rich myeloid bodies within lysosomes leading to phospholipidosis. Thus, there is significant reduction in whole kidney adenosine triphosphate levels, adenosine diphosphate-dependant, and dinitrophenol uncoupled respiration ultimately results in renal damages. [7] Bilvādi agada as a whole formulation might have worked in the kidney on various levels. Along with glomerular filtrates, the active principles of BA might have passed into the interior of nephron, and bound with receptors located at proximal convoluted tubules. Thus BA might have bound with the GM molecules and prevented renal damage.
For detoxification process and enzymatic activity, cells need to maintain alkalinity at intralysosomal level. BA might have maintained alkalinity at tubular levels which was raised by GM above the effective range of enzyme. Thus, BA might be preventing the consequences of nephrotoxicity induced by GM.
On the basis of results obtained from the blood and urine analysis, histopathological reports showing comparison of three groups it can also be postulated that, BA inhibits accumulation of GM in lysosomes and thus prevents phospholipidosis and renal damage. Furthermore it can also postulate that, BA enhances renal cortical mitochondrial oxidative phosphorylation which is evident by lesser proximal cellular damages in the kidneys of GM and BA treated group. Thus, BA might also help in repairing the tubular damage.
Pharmacological activities of ingredients of BA:
• Bilva -In previous studies -A. marmelos (bilva) root showed acute anti-inflammatory activity and the probable mechanism explained was inhibition of release of mediators like histamine, serotonin, and prostaglandins due to the chemical constituents like marmin, lupeol, etc. [8] In the present study, inflammatory changes were seen by GM administration. These changes might have been prevented by the chemical constituents like marmin, lupeol, etc., in bilva [9] • Tulasi -O. sanctum aqueous leaf extract showed nephroprotective activity due to chemical constituents eugenol, isoeugenol by virtue of their antioxidant activity [10] • Haridrā -Curcumin was proved to be the potential candidate for the prevention of nephrotoxicity due to its anti-oxidant, anti-inflammatory activities and an excellent safety profile [11] • Bibhitakī -Gallic acid, the active principle of T. bellirica might also act as anti-oxidant and prevent kidney damage. [12] Bilvādi agada treated group showed a significant decrease in serum creatinine and helped in the disposal of creatinine through urine indicating a protective effect of the trial drug. Hyperkalemia produced due to GM was normalized in BA treated group substantiating its 
CONCLUSION
Bilvādi agada has shown nephroprotective activity based on biochemical changes observed in Serum creatinine, Urine creatinine and potassium levels and this may be due to anti-inflammatory, diuretic, immunomodulatory, and anti-oxidant properties of drugs in BA. Histological studies also confirm its protection. Further human studies are needed to prove the efficacy of the BA as potential nephroprotective drug in clinical practice.
